News & Events

Results of Operations and Financial Condition. On May 12, 2026, Prelude Therapeutics Incorporated (the "Company") issued a press release announcing its financial results for the three months ended March 31, 2026. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.

Other Events. On April 20, 2026, Prelude issued a press release announcing the pricing of the Offering. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. Cautionary Note Regarding Forward-Looking Statements This Current Report on Form 8-K contains “forward-looking” statements within the meaning of the Securities Act, the Securities Exchange Act of 1934, as amended, and of the “safe harbor” provisions of the Private…

Entry into a Material Definitive Agreement. On April 20, 2026, Prelude Therapeutics Incorporated (“Prelude”) entered into an underwriting agreement (the “Underwriting Agreement”) with Goldman Sachs & Co. LLC and Evercore Group L.L.C. as representatives (the “Representatives”) of the underwriters named therein, pursuant to which Prelude agreed to issue and sell an aggregate of (a) 18,018,014 shares of its voting common stock, par value $0.0001 per share (the “Common Stock”), at a price of $4.4…

Other Events. The Company will present preclinical data from its lead development candidate, PRT 13722, at the AACR Annual Meeting 2026 on April 20, 2026. Based on preclinical data, we believe PRT 13722 is a highly differentiated, first-in-class, orally bioavailable, potent and highly selective KAT6A degrader. We observed the following in the preclinical data: • PRT13722, by degrading KAT6A, drives more complete disruption of KAT6A regulatory pathways than dual KAT6A/B inhibitors, resulting i…

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (c) On April 15, 2026 Prelude Therapeutics Incorporated, (the “ Company ”) announced that the Board of Directors of the Company (the “ Board ”) appointed Charles Q. Morris, M.D., age 61, as the Chief Medical Officer of the Company, effective on April 20, 2026 (the “ Appointment Date ”). Prior to joining the Company, Dr. Morris served as Chief Medic…

Other Events. As previously disclosed in the Current Report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on March 15, 2023, Prelude Therapeutics Incorporated (the “Company”) entered into an Open Market Sale Agreement SM (the “Sales Agreement”) with Jefferies LLC, as sales agent (“Jefferies”), relating to shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), pursuant to which the Company may offer and sell up to $75.0 million of it…

Results of Operations and Financial Condition. On March 10, 2026, Prelude Therapeutics Incorporated (the "Company") issued a press release announcing its financial results for the year ended December 31, 2025. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.

Results of Operations and Financial Condition. On November 12, 2025, Prelude Therapeutics Incorporated (the "Company") issued a press release announcing its financial results for the three months ended September 30, 2025. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers On November 4, 2025, the Company announced that Jane Huang, M.D. resigned as the President and Chief Medical Officer of the Company, effective on November 3, 2025 (the “Separation Date”). Dr. Huang’s resignation was not due to any disagreement with the Company on any matter relating to the Company’s operations, policies or practices. Effective as of…

of this Current Report on Form 8-K and Exhibits 99.1, 99.2, and 99.3 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to liability under that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act, or the Exchange Act, except as expressly set forth by specific reference in such a filing. Cautionary Note Regarding Forward-Looking Statemen…

Entry into a Material Definitive Agreement. Exclusive Option Agreement On November 3, 2025, Prelude Therapeutics Incorporated (the “Company”) entered into an Exclusive Option Agreement (the “Option Agreement”) with Incyte Corporation (“Incyte”) to acquire the Company’s mutative selective JAK2V617F JH2 inhibitor program (the “Program”) for patients with myeloproliferative neoplasms (“MPNs”). The Program has the potential to reduce mutant allele burden, modify disease progression, and transform…

Based in part upon the representations of Incyte in the Securities Purchase Agreement, the offering and sale of the Shares will be exempt from registration under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”). The Shares will not be registered under the Securities Act or any state securities laws and may not be offered or sold in the United States absent registration with the SEC or an applicable exemption from the registration requirements. The sale of the s…

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 15 , 2025, Mardi Dier, a Class III member of the Board of Directors (the “ Board ”) of Prelude Therapeutics Incorporated (the “ Company ”), provided notice of her intention to resign from the Board, effective October 17, 2025 (the “Effective Date”). Ms. Dier's decision to resign was not the result of any disagreement with the Company on…

Results of Operations and Financial Condition. On August 14, 2025, Prelude Therapeutics Incorporated (the "Company") issued a press release announcing its financial results for the three months ended June 30, 2025. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Appointment of New Director On June 11, 2025, upon the recommendation of the Nominating and Corporate Governance Committee (the “ Governance Committee ”) of the Board of Directors (the “ Board ”) of Prelude Therapeutics Incorporated (the “ Company ”), the Board appointed Paul Scherer, M.D., as a Class III director and as a member of the Compensatio…

Results of Operations and Financial Condition. On May 6, 2025, Prelude Therapeutics Incorporated (the "Company") issued a press release announcing its financial results for the three months ended March 31, 2025. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On March 27, 2025, Prelude Therapeutics Inc (the “Company”) received a letter (the “Bid Price Notice”) from the Listing Qualifications staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the closing bid price of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), for the prior 30 consecutive business days, the Company was not in c…

Results of Operations and Financial Condition. On March 10, 2025, Prelude Therapeutics Incorporated (the "Company") issued a press release announcing its financial results for the year ended December 31, 2024. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.

of the Prior 8-Ks is incorporated herein by reference. Employment Agreement with Bryant D. Lim In connection with his appointment as permanent Chief Financial Officer, the Company and Mr. Lim have entered into an Amended Executive Employment Agreement (the “CFO Agreement”), which provides for the following compensation terms: a base annual salary of $483,000 (the “Base Salary”) and eligibility for a potential bonus of up to 40% of the Base Salary, the latter of which is discretionary based on…